The role of opioids in cancer pain management

Pain Practice

Volumn 5, Issue 1, 2005, Pages 43-54

  Fukshansky, Mikhail ^a   Are, Madhuri ^a   Burton, Alien W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer pain; Opioid rotation; Opioids

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CODEINE; DEXTROPROPOXYPHENE; DOCUSATE SODIUM; FENTANYL; FENTANYL CITRATE; HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; IBUPROFEN; KRISTALOSE; LACTULOSE; METHADONE; MORPHINE; MORPHINE SULFATE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORCO; OPIATE; ORAMORPH SR; OXYCODONE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PHENOBARBITAL; PHENOTHIAZINE; PHENYTOIN; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; VICOPROPHEN;

ANALGESIA; BIOEQUIVALENCE; CANCER PAIN; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DELIRIUM; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RELEASE; HALLUCINATION; HUMAN; HYPOTENSION; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUROTOXICITY; PAIN ASSESSMENT; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; XEROSTOMIA;

EID: 27944434265     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2005.05106.x     Document Type: Review

References (48)

1. Foley KM. The treatment of cancer pain. N Engl J Med. 1985;313:84-95.
2. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592-596.
3. Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353:1695-1700.
4. Bruera E, Kim HN. Cancer Pain. JAMA. 2003; 290:2476-2479.
5. Regan JM, Peng P. Neurophysiology of cancer pain. Cancer Control. 2000;7:111-119.
6. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence, and characteristics. Pain. 1990;41:273-281.
7. Cherney N. New strategies in opioid therapy for cancer pain. J Oncol Manage. 2000;9:8-15.
8. World Health Organization. Cancer Pain Relief. Geneva: WHO Office of Publications; 1986.
9. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology-v.1.2004. Cancer Pain. Geneva: WHO Office of Publications; 2004.
10. World Health Organization. Cancer Pain Relief, 2nd edn. Geneva: WHO office of Publication; 1996.
11. World Health Organization. National Cancer Control Programmes. Political and Managerial Guidelines. Executive Summary, 2002.
12. Cleary JF. Cancer pain manage. Cancer Control. 2000;7:120-131.
13. Portenoy RK. Contemporary Diagnosis and Management of Pain in Oncologic and AIDS Patients, 3rd edn. Newton, PA: Handbooks in Health Care Co.; 2000.
14. Burton AW, Driver LC, Mendoza TR, Syed G. Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises. Clin J Pain. 2004;20:195-197.
15. Pasternak GW. The Pharmacology of mu analgesics: from patient to genes. Neuroscientist. 2001;7:220-231.
16. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science. 1973;179:1011-1014.
17. Levy MH. Pain management in advanced cancer. Semin Oncol. 1985;12:394-410.
18. Snyder SH, Pasternak GW. Historical review: opioid receptors. Trends Pharmacol Sci. 2003;24:198-205.
19. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol. 2002; 20:348-352.
20. Switzer ND, Rajagopal A. Cancer Pain Emergencies. Holland: Frei Oncologic Emergencies. BC Decker; 2002.
21. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86:1856-1866.
22. McClellan K, Scott LJ. Tramadol/Paracetamol. Drugs. 2003;63:1079-1086.
23. Tawfik MO, Elborolossy K, Nasr F. Tramadol hydrochloride in the relief of cancer pain: a double blind comparison against sustained release morphine. Pain. 1990; 5(suppl):337.
24. Lurcott G. The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone. Anesth Prog. 1999;45:154-156.
25. Dhaliwal HS, Sloan P, Arkinstall WW, et al. Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain. J Pain Symptom Manage. 1995;10:612-623.
26. Otton SV, Schadel M, Cheung SW, et al. CYP 2D6 phenotype determines the metabolic conversion of hydrocodone to hydromprphone. Clin Pharmcol Ther. 1993;54:463-472.
27. Christup LL. Morphine metabolites. Acta Anaesthesiol Scand. 1997;41:116-122.
28. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharamacological characterization of morphine 6-beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther. 1989;215:477-483.
29. Donnely S, Davis M, Walsh D, Naughton M. Morphine in cancer pain management: a practical guide. Support Care Cancer. 2002;10:13-35.
30. Hanks GW, De Conno F, Ripamonti C, et al. Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care. BM J. 1996;312:823-826.
31. Babul N, Drake AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage. 1995;10:184-186.
32. Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med. 2001;15:26-34.
33. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001;9:84-96.
34. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics oxycodone. Clin Pharmacol Ther. 1998;64:603-611.
35. Ross FB, Wallis SC, Smith MT. Co-administration of sub-antinociceptive synergy with reduced CNS side-effects in rats. Pain. 2000;84:421-428.
36. Davis M, Varga J, Dickerson D, Walsh D, LeGrand S, Lagman R. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamic, and controversy. Support Care Cancer. 2003;11:84-92.
37. Reder FR. Opioid formulations: tailoring to the needs in chronic pain. Eur J Pain. 2001;5(suppl A):109-111.
38. Muijsers R, Wagstaff A. Transdermal Fentanyl an update review of its pharmacologic properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001;61:2289-2307.
39. Gourlay GK. Treatment of cancer pain with transdermal fentanyl. Lancet Oncol. 2001;2:165-172.
40. Egbert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are noncompetitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 1995;187:165-168.
41. Bruera D, Sweeney C. Methadone use in cancer patients with pain; a review. J Palliat Med. 2002;5:127-138.
42. Mercadante S, Casuccio A, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol. 1999;17:3307-3312.
43. Nauck F, Ostgathe C, Klaschik E. Opioid swiching from high dose morphine to methadone. European Journal of Palliative Care Abstracts of the 7th Congress of the European Association of Palliative Care, 104. 2001. Abstracts.
44. Clarke RS. Nausea and vomiting. Br J Anaesth. 1984;56:19-27.
45. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996;78:852-857.
46. Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for abdominal pain associated with malignancy: a meta-analysis. Anesth Analg. 1995;80:290-295.
47. Smith TJ, Staats PS, Deer T, et al. Randomized comparison of Intrathecal Drug Delivery System (IDDS) + Comprehensive Medical Management (CMM) vs. CMM alone for unrelieved cancer pain. J Clin Oncol. 2002;20:4040-4049.
48. Du Pen S, Kharasch ED, Williams A, et al. Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. Pain. 1992;49:293-300.